Xie Q, Liu Y, Liu G, Yang N, Yin G. Diffuse proliferative glomerulonephritis associated with dermatomyositis with nephrotic syndrome. Rheumatol Int. 2010 Apr. 30(6):821-5. [QxMD MEDLINE Link].
[Guideline] Yates M, Watts RA, Bajema IM, Cid MC, Crestani B, Hauser T, et al. EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis. 2016 Sep. 75 (9):1583-94. [QxMD MEDLINE Link]. [Full Text].
[Guideline] Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. KDIGO Clinical Practice Guideline for Glomerulonephritis Chapter 13: Pauci-immune focal and segmental necrotizing glomerulonephritis. Kidney Int Suppl (2011). 2012 Jun. 2 (2):233-239. [QxMD MEDLINE Link]. [Full Text].
[Guideline] Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. KDIGO Clinical Practice Guideline for Glomerulonephritis Chapter 9: Infection-related glomerulonephritis. Kidney Int Suppl (2011). 2012 Jun. 2 (2):200-208. [QxMD MEDLINE Link]. [Full Text].
Prendecki M, Clarke C, Cairns T, Cook T, Roufosse C, Thomas D, et al. Anti-glomerular basement membrane disease during the COVID-19 pandemic. Kidney Int. 2020 Sep. 98 (3):780-781. [QxMD MEDLINE Link].
[Guideline] Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. KDIGO Clinical Practice Guideline for Glomerulonephritis Chapter 12: Lupus nephritis. Kidney Int Suppl (2011). 2012 Jun. 2 (2):221-232. [QxMD MEDLINE Link]. [Full Text].
[Guideline] Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. KDIGO Clinical Practice Guideline for Glomerulonephritis Chapter 14: Anti-glomerular basement membrane antibody glomerulonephritis. Kidney Int Suppl (2011). 2012 Jun. 2 (2):240-242. [QxMD MEDLINE Link]. [Full Text].
Almaani S, Meara A, Rovin BH. Update on Lupus Nephritis. Clin J Am Soc Nephrol. 2017 May 8. 12 (5):825-835. [QxMD MEDLINE Link]. [Full Text].
Vachvanichsanong P, Dissaneewate P, McNeil E. Diffuse proliferative glomerulonephritis does not determine the worst outcome in childhood onset lupus nephritis: a 23-year experience in a single centre. Nephrol Dial Transplant. 2009 Apr 25. [QxMD MEDLINE Link].
Pesce F, Stea ED, Rossini M, Fiorentino M, Piancone F, Infante B, et al. Glomerulonephritis in AKI: From Pathogenesis to Therapeutic Intervention. Front Med (Lausanne). 2020. 7:582272. [QxMD MEDLINE Link]. [Full Text].
van Daalen EE, Jennette JC, McAdoo SP, Pusey CD, Alba MA, Poulton CJ, et al. Predicting Outcome in Patients with Anti-GBM Glomerulonephritis. Clin J Am Soc Nephrol. 2018 Jan 6. 13 (1):63-72. [QxMD MEDLINE Link].
Hiramatsu N, Kuroiwa T, Ikeuchi H, et al. Revised classification of lupus nephritis is valuable in predicting renal outcome with an indication of the proportion of glomeruli affected by chronic lesions. Rheumatology (Oxford). 2008 May. 47(5):702-7. [QxMD MEDLINE Link].
Demircin G, Oner A, Erdogan O, et al. Long-term efficacy and safety of quadruple therapy in childhood diffuse proliferative lupus nephritis. Ren Fail. 2008. 30(6):603-9. [QxMD MEDLINE Link].
Haas M, Rahman MH, Cohn RA, et al. IgA nephropathy in children and adults: comparison of histologic features and clinical outcomes. Nephrol Dial Transplant. 2008 Aug. 23(8):2537-45. [QxMD MEDLINE Link].
Lazarus B, John GT, O'Callaghan C, Ranganathan D. Recent advances in anti-neutrophil cytoplasmic antibody-associated vasculitis. Indian J Nephrol. 2016 Mar-Apr. 26 (2):86-96. [QxMD MEDLINE Link]. [Full Text].
Nasr SH, Collins AB, Alexander MP, Schraith DF, Herrera Hernandez L, Fidler ME, et al. The clinicopathologic characteristics and outcome of atypical anti-glomerular basement membrane nephritis. Kidney Int. 2016 Apr. 89 (4):897-908. [QxMD MEDLINE Link].
Sahin GM, Sahin S, Kantarci G, Ergin H. Mycophenolate mofetil treatment for therapy-resistant glomerulopathies. Nephrology (Carlton). 2007. Jun;12(3):285-8. [QxMD MEDLINE Link].
Opastirakul S, Chartapisak W. Pulse cyclophosphamide induction treatment in Thai children with diffuse proliferative lupus nephritis. Nephrology (Carlton). 2011 Dec 19. [QxMD MEDLINE Link].
Tani C, Mosca M, d'Ascanio A, Neri R, Tavoni A, Carli L, et al. [Long term outcome of treatment of diffuse proliferative glomerulonephritis with pulse steroids and short course pulse cyclophosphamide]. Reumatismo. 2010 Jul-Sep. 62(3):215-20. [QxMD MEDLINE Link].
Chan TM, Li FK, Tang CS. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N Engl J Med. 2000 Oct 19. 343(16):1156-62. [QxMD MEDLINE Link].
Ginzler EM, Dooley MA, Aranow C, et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med. 2005 Nov 24. 353(21):2219-28. [QxMD MEDLINE Link]. [Full Text].
Parikh SV, Rovin BH. Current and Emerging Therapies for Lupus Nephritis. J Am Soc Nephrol. 2016 Oct. 27 (10):2929-2939. [QxMD MEDLINE Link]. [Full Text].
Tektonidou MG, Dasgupta A, Ward MM. Risk of End-Stage Renal Disease in Patients With Lupus Nephritis, 1971-2015: A Systematic Review and Bayesian Meta-Analysis. Arthritis Rheumatol. 2016 Jun. 68 (6):1432-41. [QxMD MEDLINE Link]. [Full Text].
Bao H, Liu ZH, Xie HL, et al. Successful treatment of class V+IV lupus nephritis with multitarget therapy. J Am Soc Nephrol. 2008 Oct. 19(10):2001-10. [QxMD MEDLINE Link].
Imran TF, Yick F, Verma S, Estiverne C, Ogbonnaya-Odor C, Thiruvarudsothy S, et al. Lupus nephritis: an update. Clin Exp Nephrol. 2016 Feb. 20 (1):1-13. [QxMD MEDLINE Link].
Plantinga LC, Patzer RE, Drenkard C, Kramer MR, Klein M, Lim SS, et al. Association of time to kidney transplantation with graft failure among U.S. patients with end-stage renal disease due to lupus nephritis. Arthritis Care Res (Hoboken). 2014 Sep 23. [QxMD MEDLINE Link].
Glassock RJ. IgA nephropathy: challenges and opportunities. Cleve Clin J Med. 2008. Aug;75(8):569-76. [QxMD MEDLINE Link]. [Full Text].
[Guideline] Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. KDIGO Clinical Practice Guideline for Glomerulonephritis Chapter 10: Immunoglobulin A nephropathy. Kidney Int Suppl (2011). 2012 Jun. 2 (2):209-217. [QxMD MEDLINE Link]. [Full Text].
Kusunoki Y, Namba-Hamano T, Kakimoto T, Yamamoto S, Ikeda N, Wakabayashi K, et al. A case of proliferative glomerulonephritis with immunoglobulin A1-lambda deposits successfully treated by chemotherapy. CEN Case Rep. 2020 Nov. 9 (4):326-332. [QxMD MEDLINE Link]. [Full Text].
Jindal KK. Management of idiopathic crescentic and diffuse proliferative glomerulonephritis: evidence-based recommendations. Kidney Int Suppl. 1999 Jun. 70:S33-40. [QxMD MEDLINE Link].
[Guideline] Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. KDIGO Clinical Practice Guideline for Glomerulonephritis Chapter 2: General principles in the management of glomerular disease. Kidney Int Suppl (2011). 2012 Jun. 2 (2):156-162. [QxMD MEDLINE Link]. [Full Text].
[Guideline] Yuzawa Y, Yamamoto R, Takahashi K, Katafuchi R, Tomita M, Fujigaki Y, et al. Evidence-based clinical practice guidelines for IgA nephropathy 2014. Clin Exp Nephrol. 2016 Aug. 20 (4):511-535. [QxMD MEDLINE Link]. [Full Text].